Zymergen, a five-year-old company that manufacturers molecules for a wide array of uses and industries, has closed on $400 million in Series C funding led by one of its earlier investors, the SoftBank Vision Fund. Even in a world where triple-digit million-dollar rounds have become de rigueur, the amount stands out, as does the company, […]